Back to Search
Start Over
Outcomes for newly diagnosed patients with acute myeloid leukemia dosed on actual or adjusted body weight
- Source :
- Cancer Chemotherapy and Pharmacology. 76:691-697
- Publication Year :
- 2015
- Publisher :
- Springer Science and Business Media LLC, 2015.
-
Abstract
- Data from solid tumor malignancies suggest that actual body weight (ABW) dosing improves overall outcomes. There is the potential to compromise efficacy when chemotherapy dosages are reduced, but the impact of dose adjustment on clinical response and toxicity in hematologic malignancies is unknown. The purpose of this study was to evaluate the outcomes of utilizing a percent of ABW for acute myeloid leukemia (AML) induction chemotherapy dosing.This retrospective, single-center study included 146 patients who received 7 + 3 induction (cytarabine and anthracycline) for treatment of AML. Study design evaluated the relationship between percentage of ABW dosing and complete response (CR) rates in patients newly diagnosed with AML.Percentage of ABW dosing did not influence CR rates in patients undergoing induction chemotherapy for AML (p = 0.83); nor did it influence rate of death at 30 days or relapse at 6 months (p = 0.94). When comparing patients dosed at 90-100 % of ABW compared to90 % ABW, CR rates were not significantly different in patients classified as poor risk (p = 0.907). All favorable risk category patients obtained CR.Preemptive dose reductions for obesity did not influence CR rates for patients with AML undergoing induction chemotherapy and did not influence the composite endpoint of death at 30 days or disease relapse at 6 months.
- Subjects :
- Adult
Male
Oncology
Cancer Research
medicine.medical_specialty
Dose
medicine.medical_treatment
Antineoplastic Agents
Toxicology
Article
Body Mass Index
Cohort Studies
Young Adult
Recurrence
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
medicine
Humans
Anthracyclines
Drug Dosage Calculations
Pharmacology (medical)
Obesity
Dosing
Aged
Retrospective Studies
Pharmacology
Chemotherapy
business.industry
Body Weight
Remission Induction
Cytarabine
Induction chemotherapy
Myeloid leukemia
Retrospective cohort study
Induction Chemotherapy
Middle Aged
Overweight
Surgery
Leukemia, Myeloid, Acute
Drug Resistance, Neoplasm
Female
business
Body mass index
Follow-Up Studies
medicine.drug
Subjects
Details
- ISSN :
- 14320843 and 03445704
- Volume :
- 76
- Database :
- OpenAIRE
- Journal :
- Cancer Chemotherapy and Pharmacology
- Accession number :
- edsair.doi.dedup.....2a091664c5c6d53649e4811907c8984a